Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Patients with chronic hepatitis B and treated with entecavir for over 6 months (with no
previous other antiviral treatment) will be invited to participate in this study. They will
be eligible if their liver tests are normal and their viral load is undetectable. Patients
will be switched to lamivudine treatment to assess whether lamivudine can maintain adequate
suppression of the hepatitis B virus after successful treatment with entecavir. Patients will
be monitored closely after switching treatment at 1 months and then every 3 monthly. If there
is any evidence of increase in viral load then patients will be given the option of changing
back to entecavir.